Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ponatinib Hydrochloride

FDA-approved product (tablet, oral), marketed as Iclusig, Ponatinib Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ponatinib Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute lymphoblastic leukemia
  • Chronic myelogenous leukemia
  • Lymphoid leukemia
  • Myeloid leukemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bcr-abl tyrosine kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ponatinib Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ponatinib Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST

    NCT03171389 · start 2017-03-22

    Registered record
    Registry ID
    NCT03171389
    Conditions
    GIST, Malignant; KIT Exon 13 Mutation; KIT Gene Mutation
    Interventions
    Ponatinib 30 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2017-03-22
    Completion
    2020-09-22
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGIST, Malignant; KIT Exon 13 Mutation; KIT Gene Mutation
    InterventionPonatinib 30 MG
    PhasePhase 2
    Registry statusUnknown

  • Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium

    NCT03678454 · start 2017-02-03

    Registered record
    Registry ID
    NCT03678454
    Conditions
    Chronic Myeloid Leukemia; CML; Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia; Ph+ ALL
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-02-03
    Completion
    2022-03-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia; CML; Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia; Ph+ ALL
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

    NCT02829840 · start 2016-09

    Registered record
    Registry ID
    NCT02829840
    Conditions
    Leukemia; FLT3-Mutated Acute Myeloid Leukemia; FLT3-Mutated High-Risk Myelodysplastic Syndrome
    Interventions
    Ponatinib; 5-azacytidine; Phone Calls
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2016-09
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; FLT3-Mutated Acute Myeloid Leukemia; FLT3-Mutated High-Risk Myelodysplastic Syndrome
    InterventionPonatinib; 5-azacytidine; Phone Calls
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

    NCT02629692 · start 2016-06-27

    Registered record
    Registry ID
    NCT02629692
    Conditions
    Healthy (For Part A); Chronic Myeloid Leukemia (for Part B and C)
    Interventions
    Vodobatinib (K0706) capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2016-06-27
    Completion
    2025-01-03
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy (For Part A); Chronic Myeloid Leukemia (for Part B and C)
    InterventionVodobatinib (K0706) capsules
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib

    NCT02398825 · start 2016-06-23

    Registered record
    Registry ID
    NCT02398825
    Conditions
    Chronic Myeloid Leukemia; Chronic Phase; Adults
    Interventions
    Ponatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-06-23
    Completion
    2022-12-27
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia; Chronic Phase; Adults
    InterventionPonatinib
    PhasePhase 2
    Registry statusTerminated

  • Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia

    NCT02776605 · start 2016-06

    Registered record
    Registry ID
    NCT02776605
    Conditions
    ALL
    Interventions
    Prednisone; Vincristine; Daunorubicin; Prednisone; Ponatinib; Mercaptopurine; Methotrexate; VP-16; ARA-C:; TIT; Ponatinib; Autologous transplantation; Allo transplantation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2016-06
    Completion
    2023-08
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALL
    InterventionPrednisone; Vincristine; Daunorubicin; Prednisone +9 more
    PhasePhase 2
    Registry statusUnknown

  • Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma

    NCT01888562 · start 2016-01

    Registered record
    Registry ID
    NCT01888562
    Conditions
    Endometrial Neoplasms
    Interventions
    Ponatinib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2016-01
    Completion
    2023-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Neoplasms
    InterventionPonatinib
    PhaseNot applicable
    Registry statusWithdrawn

  • Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose

    NCT03933852 · start 2015-07-08

    Registered record
    Registry ID
    NCT03933852
    Conditions
    Chronic Myeloid Leukemia, Chronic Phase
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2015-07-08
    Completion
    2024-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia, Chronic Phase
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

    NCT01935336 · start 2013-09-24

    Registered record
    Registry ID
    NCT01935336
    Conditions
    Adenocarcinoma of the Lung; Extensive Stage Small Cell Lung Cancer; Limited Stage Small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Recurrent Small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
    Interventions
    Ponatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-09-24
    Completion
    2017-11
    Enrolment
    171

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Lung; Extensive Stage Small Cell Lung Cancer; Limited Stage Small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer +4 more
    InterventionPonatinib
    PhasePhase 2
    Registry statusCompleted

  • Ponatinib in Advanced NSCLC w/ RET Translocations

    NCT01813734 · start 2013-09

    Registered record
    Registry ID
    NCT01813734
    Conditions
    Non Small Cell Lung Cancer
    Interventions
    Ponatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-09
    Completion
    2018-08
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer
    InterventionPonatinib
    PhasePhase 2
    Registry statusCompleted

  • Ponatinib for FLT3-ITD Acute Myelogenous Leukemia

    NCT02428543 · start 2013-07

    Registered record
    Registry ID
    NCT02428543
    Conditions
    Acute Myeloid Lukemia
    Interventions
    Ponatinib and Cytarabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2013-07
    Completion
    2023-10-03
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Lukemia
    InterventionPonatinib and Cytarabine
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

    NCT01883219 · start 2013-06

    Registered record
    Registry ID
    NCT01883219
    Conditions
    Philadelphia Chromosome Positive Acute Lymphocytic Leukemia; Stem Cell Transplantation; Minimal Residual Disease
    Interventions
    TKIs
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2013-06
    Completion
    2017-11
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPhiladelphia Chromosome Positive Acute Lymphocytic Leukemia; Stem Cell Transplantation; Minimal Residual Disease
    InterventionTKIs
    PhasePhase 2
    Registry statusUnknown

  • Ponatinib for Advanced Medullary Thyroid Cancer

    NCT01838642 · start 2013-03

    Registered record
    Registry ID
    NCT01838642
    Conditions
    Thyroid Neoplasms
    Interventions
    Ponatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-03
    Completion
    2016-01
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThyroid Neoplasms
    InterventionPonatinib
    PhasePhase 2
    Registry statusTerminated

  • Ponatinib for Squamous Cell Lung and Head and Neck Cancers

    NCT01761747 · start 2013-01

    Registered record
    Registry ID
    NCT01761747
    Conditions
    Non-Small Cell Lung Cancer, Head and Neck Cancer
    Interventions
    ponatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2013-01
    Completion
    2014-06
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer, Head and Neck Cancer
    Interventionponatinib
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

    NCT01650805 · start 2012-06

    Registered record
    Registry ID
    NCT01650805
    Conditions
    Chronic Myeloid Leukemia
    Interventions
    ponatinib; imatinib (Gleevec/ Glivec)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2012-06
    Completion
    2013-10
    Enrolment
    307

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia
    Interventionponatinib; imatinib (Gleevec/ Glivec)
    PhasePhase 3
    Registry statusTerminated